NGM Biopharmaceuticals is a private South San Francisco biotech translating biology into first-in-class medicines, anchored by its GDF15/GFRAL antagonist NGM120 in Phase 2 trials for cancer cachexia and hyperemesis gravidarum.
Diana Peng Bockus is the Chief Executive Officer of NGM Biopharmaceuticals, a South San Francisco biotech developing first-in-class medicines for liver disease, oncology, and ophthalmology. Appointed CEO in April 2025, she joined the company in 2020 to lead business development and restructured a pivotal Merck partnership that freed NGM to build a wholly owned pipeline. A Stanford and Wharton graduate with roots in management consulting at Bain & Company, she now steers a privately held biotech backed by $515M in total funding, focused on rare diseases like primary sclerosing cholangitis and hyperemesis gravidarum.